Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities
Open Access
- 19 January 2026
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 213
Abstract
Polycystic Ovary Syndrome (PCOS) is characterized by a self-perpetuating vicious cycle between insulin resistance (IR) and hyperandrogenism (HA). While lifestyle management remains the internationally recommended first-line treatment, current clinical management, primarily relying on combined oral contraceptives and metformin, offers symptomatic relief or “masking” of the phenotype but fails to adequately disrupt this core pathophysiological loop, while also carrying potential intergenerational safety concerns. This review systematically evaluates the paradigm shift toward mechanism-based precision medicine. First, we analyze emerging precision-targeted therapies that intervene in specific pathological nodes: (1) metabolic regulators (e.g., GLP-1RAs, SGLT2i, and brown adipose tissue (BAT) activators) that target systemic glucotoxicity and the novel “BAT-Ovarian axis”; (2) neuroendocrine modulators (e.g., NK3R antagonists) that act as negative modulators of the hyperactive GnRH pulse generator; and (3) innovative androgen synthesis inhibitors (e.g., Artemisinins) that utilize a degradation-at-source mechanism. Complementing these, we explore the strategic value of Natural Products through the lens of “Network Pharmacology”, highlighting their ability to restore systemic homeostasis via multi-target modulation. Finally, we address critical translational challenges, specifically the need to establish long-term reproductive and offspring safety, providing a roadmap for developing true disease-modifying treatments for PCOS. Distinct from reviews limited to isolated therapeutic modalities, this article uniquely bridges current clinical management with emerging organ-specific precision targets and natural product networks.Keywords
Funding Information
- National Natural Science Foundation of China (82273795)
- National Natural Science Foundation of China (21877020)
- Guangdong Natural Science Funds for Distinguished Young Scholar (2017A030306031)
- Natural Science Foundation of Guangdong Province (2023A1515030041)
This publication has 103 references indexed in Scilit:
- Therapeutic perspective of postbiotics in managing health of women with polycystic ovarian syndrome: a holistic approachInflammopharmacology, 2025
- Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trialNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- Ketogenic Diet as Medical Prescription in Women with Polycystic Ovary Syndrome (PCOS)Current Nutrition Reports, 2023
- Quercetin Attenuates Atherosclerotic Inflammation by Inhibiting Galectin‐3‐NLRP3 Signaling PathwayMolecular Nutrition & Food Research, 2021
- Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro FertilizationJAMA Network Open, 2020
- The Effects of Probiotic Supplementation on Clinical Symptom, Weight Loss, Glycemic Control, Lipid and Hormonal Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled TrialsProbiotics and Antimicrobial Proteins, 2019
- Quercetin Attenuates Adhesion Molecule Expression in Intestinal Microvascular Endothelial Cells by Modulating Multiple PathwaysDigestive Diseases and Sciences, 2018
- Depression and Anxiety in Polycystic Ovary Syndrome: Etiology and TreatmentCurrent Psychiatry Reports, 2017
- Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant Vaccinium vitis-idaeaMolecular Nutrition & Food Research, 2010
- Estrogen Plus Progestin and Risk of Venous ThrombosisJAMA, 2004